Head and neck cancers (HNCs) are a heterogeneous group, consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth; the salivary glands; the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx; the nose, sinuses, and related structures; the larynx; and the thyroid. HNCs usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck — more than 80% of all HNCs are squamous cell carcinomas. HNCs are common in several regions across the globe and account for 600,000 new cases annually worldwide.

1. EpiCast Report: Head and Neck Cancers -
Epidemiology Forecast to 2024
“Future Market Trends of EpiCast Report Forecast
to 2024.”
Published on - 01 February, 2016| Number of pages : 80
Single User Price: $2000
• The EpiCast Report is in-depth, high quality, transparent and
market-driven, providing expert analysis of disease trends in the
7MM.
• The HNCs epidemiology report is written and developed by
Masters- and PhD-level epidemiologists.

2. Head and neck cancers (HNCs) are a heterogeneous group, consisting of
cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate,
and other parts of mouth; the salivary glands; the pharynx, including the
tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other
mouth/pharynx; the nose, sinuses, and related structures; the larynx; and the
thyroid.
HNCs usually begin in the squamous cells that line the moist mucosal
surfaces of the tissues and organs of the head and neck — more than 80% of
all HNCs are squamous cell carcinomas. HNCs are common in several regions
across the globe and account for 600,000 new cases annually worldwide.

3. • GlobalData epidemiologists forecast an increase in diagnosed incident cases
of HNCs in the 7MM from 151,393 diagnosed incident cases in 2014 to
174,056 diagnosed incident cases in 2024, with an Annual Growth Rate (AGR)
of 1.50% during the forecast period. In 2024, the US will have the highest
number of diagnosed incident cases of HNCs in the 7MM, with 65,663
diagnosed incident cases, whereas the UK will have the lowest number of
diagnosed incident cases of HNCs, with 12,702 diagnosed incident cases in
2024.
• The diagnosed incident cases of thyroid cancer in the 7MM are expected to
increase from 93,225 diagnosed incident cases in 2014 to 123,504 diagnosed
incident cases in 2024, with an AGR of 3.25% during the forecast period. In
2024, the US will have the highest number of diagnosed incident cases of
thyroid cancer in the 7MM with 81,286 diagnosed incident cases, whereas
Spain will have the lowest number of diagnosed incident cases of thyroid
cancer with 3,233 diagnosed incident cases in 2024.
Click Here To Check Complete Report

4. Scope:
1.The Head and neck cancers (HNCs) EpiCast Report provides an overview of the
risk factors, comorbidities, and the global and historical trends for HNCs in the
seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan).
2. It includes a 10-year epidemiological forecast of the diagnosed incident cases
of HNCs segmented into three sub-groups: cancers of the lip, oral cavity, and
pharynx; cancers of the nose, sinuses, and related structures; and cancers of the
larynx, in these markets.
3.It also includes a 10-year epidemiological forecast for the five-year diagnosed
prevalent cases of HNCs (excluding nose, sinuses, and related cancers).
Additionally, it includes a 10-year epidemiological forecast for the diagnosed
incident cases and the five-year diagnosed prevalent cases of thyroid cancer in
the 7MM.
4.The diagnosed incident cases of HNCs (excluding nose, sinuses, and related
cancers) and thyroid cancer are segmented by age, sex, clinical stage at diagnosis,
and histology
Download Sample Brochure

5. Reasons to buy
The HNCs EpiCast report will allow you to
• Develop business strategies by understanding the trends shaping and driving the
global HNCs market.
•Quantify patient populations in the global HNCs market to improve product
design, pricing and launch plans.
•Organize sales and marketing efforts by identifying the age groups and sex that
present the best opportunities for HNCs therapeutics in each of the markets
covered.
Make an Inquiry Before Buy

6. EpiCast Report: Head and Neck Cancers -
Epidemiology Forecast to 2024
A detailed qualitative analysis of the factors responsible for driving and restraining
growth of the EpiCast Report and future opportunities are provided in the report.
Contact:
1-302-684-6088
sales@marketintelreports.com
www.marketintelreports.com
Click here to order a copy of
EpiCast Report

7. EpiCast Report: Head and Neck Cancers -
Epidemiology Forecast to 2024
A detailed qualitative analysis of the factors responsible for driving and restraining
growth of the EpiCast Report and future opportunities are provided in the report.
Contact:
1-302-684-6088
sales@marketintelreports.com
www.marketintelreports.com
Click here to order a copy of
EpiCast Report